FDA Approves Third COVID-19 Antibody Treatment for Emergency Use – Pulmonology Advisor
A third antibody treatment designed to keep high-risk COVID-19 patients from being hospitalized was approved for emergency use by the FDA.
A third antibody treatment designed to keep high-risk COVID-19 patients from being hospitalized was approved for emergency use by the FDA.
Investigators evaluated the real-world effects of prior pneumococcal vaccination in patients 65 years of age and older with community-acquired pneumonia.
Researchers assessed the association between OSA, COVID-19 severity, and 30-day readmission rates among veterans receiving care at a Chicago VA hospital.
Researchers assessed the link between the pre-lung transplant BMI of recipients and donors and post-transplant complications in recipients.
Frequent users had increased urine lead and uranium levels versus occasional users
Researchers evaluated the efficacy and safety of endobronchial valve treatment in patients with emphysema and persistent air leak.
Researchers conducted a real-world study of the effects of elexacaftor/tezacaftor/ivacaftor on lung static volumes and hyperinflation in cystic fibrosis.
Researchers explored the effects of using race-neutral spirometry equations to define airflow obstruction in COPD and using z-scores to define obstruction thresholds.
Despite patient beliefs, no impact seen on severity, duration of cough
Researchers assessed the rate of pulmonary post-surgical complications in patients with type 2 diabetes who used GLP-1 RAs before same-day emergency surgery.
Investigators compared the severity of COVID-19 outcomes in US veterans with and without chronic lung diseases.